Celgene bets $7.2B on Receptos autoimmune med; Teva sells off 22 generics to ANI Pharma;

@FiercePharma: Almac's launch of Singapore APAC HQ also eyes regional growth of small biotechs. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: Why did FDA ban Emcure India plant? Recall of drugs manufactured for Teva may provide a clue. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: AZ's Iressa gets back in the game with first-line FDA approval in lung cancer. Report | Follow @CarlyHFierce

> Celgene ($CELG) extended its spate of deals with a $7.2 billion buyout of Receptos ($RCPT) and its autoimmune drug ozanimod, in Phase III testing for ulcerative colitis and multiple sclerosis. Report

> ANI Pharmaceuticals ($ANIP) snapped up 22 generic drugs from Teva Pharmaceuticals ($TEVA) for $25 million. Report

> Sanofi Pasteur rolled out the first shipments of its 2015-2016 influenza shot Fluzone in the U.S. Report

> Greek pharmacists shuttered their stores Wednesday to protest a new bailout deal that would also allow non-pharmacists to open up pharmacies. Report

Medical Device News

@FierceMedDev: Swedish biotech ropes in $11M for automated HIV testing device. FierceDiagnostics item | Follow @FierceMedDev

@VarunSaxena2: ICYMI: India moving closer to implementing price controls on medical devices. Story | Follow @VarunSaxena2

@EmilyWFierce: JAMA: Noninvasive prenatal tests can pinpoint cancer in mothers. Story | Follow @EmilyWFierce

> U.K. researchers develop noninvasive, infrared-based blood glucose monitor, license it to startup. More

> Breakout Dx player Theranos keys into Medicaid with latest deal in managed care. Article

Biotech News

@FierceBiotech: Biopharma's 10 highest-paid heads of R&D. Feature | Follow @FierceBiotech

@JohnCFierce: $CELG chief Bob Hugin isn't done betting on 'binary' biotech deals--"we're going to go after them at the right time." Report | Follow @JohnCFierce

@DamianFierce: Here's the $CELG + $RCPT release. PR/Story | Follow @DamianFierce

> Takeda hands in its Velcade successor with blockbuster ambitions. More

> Sanofi carves up its org chart to deliver on a $38B pipeline promise. Report

Pharma Marketing News

> J&J chief touts $1B-plus prospects for coming psoriasis med guselkumab. More

> Dr. Reddy's spruces up corporate branding for U.S. marketing assault. Item

> Roche's atezo lines up PD-L1 data for forthcoming battle with Keytruda, Opdivo. Story

> Two agency giants duke it out for GlaxoSmithKline $900M media account. Report

> Programmatic's the latest word for targeting drug pitches to the right docs. Article

Biotech Research News

> Peptide shells provide a targeted cancer drug delivery system. Item

> Caspase-1 molecule highlighted as key player in regulating vascular ischemia. More

> Johns Hopkins team points to a new therapeutic approach to hearing loss. Report

> Penn study confirms a link between male infertility and genetic mutations. Story

> Nonviral gene therapy shrinks brain tumors in rats. Article

Diagnostics News

> Merck invests $6M in microbial diagnostics specialist OpGen. Report

> Qiagen scores FDA approval for lung cancer companion Dx. News

> Xagenic reels in $15M for point-of-care testing system. Story

> Natera joins forces with University College London for lung cancer study. Article

> CombiMatrix coasts toward growth with renewed sales push. Editor's corner

And Finally... A task force recommended investing in counseling and support programs for people at risk of Type 2 diabetes, citing studies showing the preventive effects of proper diet and exercise. Report

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.